MicroRNA-binding site polymorphisms in hematological malignancies

Agnieszka Dzikiewicz-Krawczyk

Abstract

Dysregulation of microRNA networks has been implicated in hematological malignancies. One of the reasons for disturbed miRNA-mediated regulation are polymorphisms in miRNA-binding sites (miRSNPs), which alter the strength of miRNA interaction with target transcripts. In the recent years the first findings of miRSNPs associated with risk and prognosis in hematological malignancies have been reported. From the studies described in this review miRSNPs not only emerge as novel markers of risk and prognosis but can also lead to better understanding of the role of miRNAs in regulating gene expression in health and disease.

Keywords: microRNA, miRNA-binding site polymorphism, Leukemia, Lymphoma, Myeloma, Risk, Prognosis

Introduction

The non-protein coding parts of the genome have been recognized as key players in the regulation of gene expression. Among various classes of non-coding RNAs, the best known are microRNAs (miRNA), small (~22 nucleotide) RNA molecules. miRNAs bind to complementary target sequences usually located in the 3’ untranslated region (3’UTR) of mRNAs and act predominantly by negatively regulating gene expression [1]. According to the miRBase database, a catalog of miRNA sequences in animals, plants and viruses, so far over 2500 mature human miRNAs have been characterized [2]. Since miRNAs are predicted to regulate over 60% of human protein-coding genes [3], it is not surprising that they have been shown to regulate a plethora of biological processes, including cell proliferation, apoptosis, differentiation and metabolism [4]. Several lines of evidence have demonstrated that miRNAs are required for normal hematopoiesis, while miRNA dysregulation has been associated with the pathogenesis of hematological malignancies [5,6].

The crucial step in the process of miRNA-mediated regulation of gene expression is recognition of the target transcript by miRNA. In animals this recognition is based on pairing of the nucleotides 2-7 of miRNA (so called ‘seed’ region) with complementary sequences in the mRNA, which are usually located in the 3’UTR, but can also be present in the 5’UTR or in the coding region. In addition, pairing of nucleotides 13-16 of the miRNA enhances the miRNA-mRNA interaction and the efficiency of miRNA binding depends also on target site accessibility and secondary structure of the miRNA-target duplex [7]. The requirement for a strict Watson-Crick pairing between the ‘seed’ region of miRNA and its target transcript implies that genetic variability in the 3’UTR can affect miRNA binding by destroying existing sites or creating new miRNA-mRNA interactions. Computational analysis identified hundreds of single nucleotide polymorphisms (SNPs) located within predicted and experimentally verified miRNA-binding sites or potentially creating novel sites for miRNA binding. Moreover, there is evidence for a strong negative selection on SNPs in miRNA-binding sites (miRSNPs) as compared to the entire 3’UTR sequence [8-10], which supports the functional significance of those sites. In the recent years several studies have shown association of miRSNPs with cancer and other diseases [11,12]. In the field of hematological malignancies the first evidence for a disease-associated miRSNP came in 2012 [13] and since then six other studies have been published. Here I will systematically review the so far presented evidence for the relevance of miRSNPs for leukemias, lymphomas and myeloma.

KRT81 and XPO5 in lymphomas and myeloma

The prognostic value of six SNPs located in either genes encoding proteins involved in the miRNA biogenesis or in miRNA-binding sites located in myeloma-related genes
was evaluated in 137 patients with multiple myeloma who underwent autologous stem cell transplantation [13]. Association with survival was observed for two SNPs: CC genotype of rs3660 in KRT81 conferred longer overall survival (OS), while patients with CC/AC genotype of rs11077 in XPO5 had significantly longer OS and progression-free survival (PFS) (Table 1). KRT81 belongs to a family of hair keratins which are involved in maintaining cell integrity and regulating cell motility and growth in epithelial cells, and have been described as prognostic markers in epithelial tumors [14]. The C allele of rs3660 in KRT81 reduced significantly the protein level in luciferase reporter assay in one of two myeloma cell lines (RPMI-8226). Also in healthy lymphocytes a significant reduction of KRT81 protein, but not mRNA, level was observed. Furthermore, a significant decrease of the proliferation rate of RPMI-8226 cells was observed upon silencing of the KRT81 gene, which indicates the possible mechanism underlying the better prognosis in myeloma patients carrying the CC genotype of KRT81 rs3660. However, although the authors indicate that according to bioinformatics prediction the C allele destroys binding sites for several miRNAs, results of their experiments indicate otherwise – that in myeloma cell lines and healthy lymphocytes this SNP enhances binding of some miRNAs, which results in decreased protein levels. Since levels of specific miRNAs were not controlled in the luciferase assay, it is not clear whether the observed effect is a consequence of altered miRNA binding, and if so – of which specific miRNA. rs3660 in KRT81 was also studied in Hodgkin lymphoma (HL) [15]. Here, the GG genotype was found more frequently in patients (30.9%) than in the European population (18.3%, data from the HapMap project) but this should be validated in a control group ethnically matched with patients. Further analysis showed that although rs3660 had no influence on survival of HL patients, the GG genotype is an independent risk factor for treatment-related neurological toxicity. In non-Hodgkin lymphoma (NHL), in turn, distribution of rs3660 genotypes did not differ between patients and control group but carriers of CC and CG genotypes had significantly longer OS compared to the GG genotype [16]. The studies in lymphomas did not attempt to verify whether rs3660 in KRT81 affects miRNA binding and what are the functional consequences of the polymorphism.

The second polymorphism found to affect survival of patients with multiple myeloma was rs11077 in XPO5. This miRSNP, apart from its potential impact on expression of XPO5, can also affect the whole miRNA-ome of the cell as XPO5 encodes for exportin-5, which is required for the export of precursor miRNAs from nucleus to cytoplasm where they are subject to further steps of maturation [17]. Bioinformatics analysis indicated that the C allele of XPO5 rs11077 creates a new binding site for miR-4763-5p. Indeed, luciferase reporter assay showed a significant reduction in protein levels in two myeloma cell lines. Also, in healthy lymphocytes the CC genotype was associated with slightly decreased XPO5 protein levels, but the difference did not reach statistical significance [13]. However, it remains to be established whether miR-4763-5p or another miRNA is responsible for the observed effect. Also, the mechanism by which reduced XPO5 levels could contribute to a better prognosis in multiple myeloma needs to be elucidated. rs11077 in XPO5 was also studied in Hodgkin lymphoma [15]. Here, the AC genotype was associated with longer overall and disease-free survival (DFS), as well as with lower rate of bleomycin-associated pulmonary toxicity. Better performance of heterozygous patients seems somewhat unusual and probably a replication in a larger cohort of patients could indicate which allele is associated with a better prognosis. This study did not provide any further clues for the functional significance of XPO5 rs11077.

TP53 and diffuse large B-cell lymphoma
Analysis of the sequence of a known tumor suppressor TP53 in a cohort of 491 diffuse large B-cell lymphoma (DLBCL) patients revealed a widespread variation in the TP53 3'UTR. A total of 187 novel single nucleotide variants (nSNV) and 6 known SNPs were identified. Interestingly, impact of these nSNVs on survival depended on the mutation status in the TP53 coding sequence (CDS): in patients with the wild type TP53 CDS nSNVs conferred better 5-year OS and PFS, while in patients with mutated CDS nSNVs were associated with poorer OS and PFS. Bioinformatics analysis showed that majority of the nSNVs were located in validated or putative miRNA-binding sites. Furthermore, it was shown in vitro that 3 nSNVs disrupting the binding site for miR-125b increase p53 protein levels (Table 1). However, no correlation was observed between the presence of nSNVs and expression of p53 in tumor samples, regardless of the mutational status of the TP53 CDS. This could be due to the fact that all nSNVs were analyzed collectively, while some of them may have positive and some negative effect on the p53 expression [18]. This study highlights the relevance of the interplay between miRSNPs and mutations in the coding sequence of a gene. Since the predicted effect of the majority of nSNVs was disruption of miRNA-binding sites, elevated levels of wild type tumor-suppressive p53 would be beneficial, while increased expression of mutated, oncogenic p53 would be unfavourable.

C14orf101/TMEM260 in non-Hodgkin lymphoma
Four polymorphisms chosen from a larger set of previously reported miRSNPs [9] were examined for association with cancer risk and prognosis in non-Hodgkin lymphoma. None of them was identified as a risk factor.
Table 1: Polymorphisms in miRNA-binding sites in hematological malignancies

| Gene   | SNP ID | Variants Expected to affect binding of | Disease | Cases | Controls | Parameter | OR (95% CI), p value | Effect on miRNA binding and gene/protein expression | Ref. |
|--------|--------|---------------------------------------|---------|-------|----------|-----------|----------------------|---------------------------------------------------|------|
| KRT81  | rs3660 | G > C | miR-17, miR-20a/b, miR-93, miR-106a/b, miR-519d | MM | 137 | OS | p = 0.037 | Effect on protein expression confirmed in gene reporter assay and in vivo | [13] |
|        |        |        |                                                  | HL | 139 | Treatment-related toxicity | 6.65 (1.33-33.26), p = 0.021 | Not examined | [15] |
|        |        |        |                                                  | NHL | 210 | OS | p = 0.012 | Effect on protein expression confirmed in gene reporter assay | [13] |
|        |        |        |                                                  | MM | 137 | OS | p = 0.012 | Not examined | [15] |
|        |        |        |                                                  | HL | 127 | Treatment-related toxicity | 0.49 (0.006-0.376), p = 0.004 | Not examined | [15] |
|        |        |        |                                                  | DLBCL | 491 | OS | p = 0.019 | Effect of three SNVs on miR-125b binding and protein expression confirmed in gene reporter assay | [18] |
|        |        |        |                                                  | ALL | 101 | Risk | 1.9 (1.16-3.11), p = 0.0107 | Effect on miR-337-5p binding and protein expression confirmed in gene reporter assay, effect on miRNA levels confirmed in vivo | [21] |
|        |        |        |                                                  | ALL | 140 | Risk | 3.97 (1.43-11.02), p = 0.0081 | No effect on miR-492 binding and protein expression observed in gene reporter assay | [22] |
|        |        |        |                                                  | ALL | 101 | Risk | 0.55 (0.36-0.85), p = 0.0079 | Effect on miR-510-5p binding and protein expression confirmed in gene reporter assay, no effect observed for miR-589-3p | [22] |
|        |        |        |                                                  | AML | 87 | Risk | 0.6 (0.38-0.97), p = 0.0372 | Effect on miR-18a-3p binding and protein expression confirmed in gene reporter assay | [22] |
|        |        |        |                                                  | CML | 140 | Risk | 2.4 (1.12-5.15), p = 0.0246 | No effect on miR-330-3p binding and protein expression observed in gene reporter assay | [22] |

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CDS, coding sequence; CML, chronic myeloid leukemia; DFS, disease-free survival; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NS, not significant; OR (95% CI), odds ratio (95% confidence interval); OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival.
but genotyping was performed on a small sample (96 patients and 90 controls) and should be replicated in a larger cohort. rs4901706 in C14orf101 was associated with overall survival: the AA genotype was identified as an independent predictor of longer survival in a group of 359 NHL patients. Luciferase reporter assay in the HeLa cell line showed that the G allele significantly reduced protein levels (Table 1) [19]. However, the study provided no indication as to binding of which miRNA might be affected nor the potential functional significance of altered expression of C14orf101. Since nothing is known about the functions of C14orf101, other than it encodes for a transmembrane protein, it is hard to speculate how altered levels of the protein may affect the prognosis of NHL patients. Interestingly, a team from the same university also studied rs4901706 in a group of 233 controls and 210 NHL patients who were treated at the same hospital and during the same period, and they did not report any association of the SNP with NHL risk or prognosis [16]. This discrepancy highlights the need for studying the functional relevance of miRSNPs to corroborate the findings from association studies.

NPM1 in acute myeloid leukemia
Significance of a polymorphic nucleotide T deletion (rs34351976) in the 3’UTR of NPM1 was studied in acute myeloid leukemia (AML). NPM1 encodes for nucleophosmin, a molecular chaperone shuffling between nucleus and cytoplasm. Mutations in NPM1 are found in about one-third of adult AML patients but the exact mechanism by which the mutant NPM1 protein contributes to leukemogenesis remains unclear [20]. Although no difference in the frequency of delT polymorphism was observed between AML patients and healthy controls, Cheng et al. showed that overall and relapse-free survival was significantly worse in patients carrying the homozygous delT. Bioinformatics analysis combined with luciferase reporter assay demonstrated that the delT polymorphism creates an illegitimate binding site for miR-337-5p, which results in decreased protein levels. This finding was confirmed in patient samples: levels of NPM1 mRNA were significantly lower in patients homozygous for the delT polymorphism than in the non-homozygotes (Table 1). The mechanism by which reduced levels of nucleophosmin resulting from the homozygous delT polymorphism influence outcome of AML patients remains to be elucidated [21].

5 miRSNPs in lymphoblastic and myeloid leukemias
Bioinformatics analysis of SNPs in the 3’UTRs of 137 leukemia-associated genes revealed 111 putative miRSNPs. Based on the concordance of at least two algorithms used in the analysis and the expression of predicted miRNAs in blood cells or leukemias and lymphomas, the authors selected 10 miRSNPs for genotyping in patients with childhood acute lymphoblastic leukemia (ALL), adult chronic (CML) and acute myeloid leukemia (AML), and healthy controls. The study showed that homozygous polymorphic genotypes of ETV6 rs1573613 and TLX1_rs2742038 were associated with increased ALL risk, while carriers of the variant allele of PML rs9479 were at lower risk of ALL and AML. Homozygous polymorphic genotypes of ARHGAP26_rs187729 and IRF8_rs10514611 conferred increased risk of CML. Furthermore, additive effect of risk genotypes was demonstrated in ALL and CML. Risk increased with each additional risk genotype carried by a patient and surpassed the sum of individual ORs, reaching 13.91 (4.38-44.11) for carriers of three or more risk genotypes in ALL and 4.9 (1.27-18.85) for carriers of two risk genotypes in CML. Effect of significant miRSNPs on miRNA binding was evaluated by luciferase reporter assay and confirmed for three miRSNPs: variant alleles of ARHGAP26_rs187729, ETV6_rs1573613 and PML_rs9479 were shown to affect binding of miR-18a-3p, miR-34c-5p/miR-449b-5p and miR-510-5p, respectively. TLX1_rs2742038 and IRF8_rs10514611 were predicted to enhance binding of miR-492 and miR-330-3p, respectively, but this was not confirmed experimentally (Table 1) [22]. The study demonstrated the relevance of polymorphisms in miRNA-binding sites for various types of leukemia, however, the findings should be validated in larger patient cohorts and the effect of miRSNPs on the expression of genes and proteins should be verified in vivo in patients samples. Also the mechanisms by which the miRSNPs modulate leukemia risk still needs to be elucidated, especially that the effect of miRSNPs in CML. Effect of significant miRSNPs on miRNA binding was not in line with in vivo expression in patients samples. Also the mechanisms by which the miRSNPs modulate leukemia risk still needs to be elucidated, especially that the effect of miRSNPs in ETV6 and PML on miRNA binding was not in line with their role as tumor suppressors. This suggests that more complicated miRNA regulatory networks might be affected, according to the concept of ‘competing endogenous RNAs’ (ceRNA) [23].

Conclusions
More evidence is accumulating for the involvement of deregulated miRNA networks in cancer development. Polymorphisms in miRNA-binding sites of target genes may disrupt miRNA-mediated regulation of gene expression by not only affecting the levels and function of the given protein, but can also interfere with expression of other genes targeted by the same miRNA.

So far only a few studies demonstrated the relevance of miRNA target site polymorphisms for hematological malignancies, but this number will doubtless grow in the next years. The studies presented in this review explored the significance of miRSNPs for the risk or prognosis of blood cancers to a different degree: some did not go beyond reporting a significant association, while others pursued the functional consequences of the miRSNPs. Based on the work described in this review, it is evident that a comprehensive study of miRSNPs in disease should include
several carefully planned and performed stages (Figure 1). The first step is the selection of candidate miRSNPs. Thorough scrutiny at this stage will increase the probability of finding miRSNPs of functional importance and facilitate interpretation of the results. Preferably, candidate SNPs should be searched for in genes with proven relevance for the disease in question, which will already give hint for their functional significance. Several tools are available for the prediction of the impact of SNPs on miRNA binding, e.g. miRanda [24], PITA [25], SNPinfo [26] and PolymiRTS [27], and since they use different algorithms for miRNA target prediction, it is advisable to select miRSNPs with the highest support from the available tools. The set of thus selected miRSNPs should be further narrowed down to those predicted to affect binding of miRNAs that are expressed in the relevant cell type, using databases integrating data on miRNA expression across different tissues and cell types, such as mimiRNA [28] or the non-coding RNA body map [29]. Allele and genotype frequencies of the selected miRSNPs are then assessed in appropriate patient and control groups to identify miRSNPs associated with disease risk or prognosis. For statistically significant miRSNPs their impact on binding of miRNAs predicted by the in silico analysis should be verified, ideally both in vitro and in vivo. Gene reporter assays (e.g. luciferase assay) allow to identify specific miRNAs which bind differentially to the wild-type and variant 3’UTRs. Depending on whether or not the miRNA of interest is expressed in the cell line used in luciferase assay, miRNA mimics and/or inhibitors need to be used in the assay to ensure that the observed effect can be attributed to the specific miRNA. mRNA and protein expression should be also compared between different genotypes in vivo in relevant samples, taking into account levels of specific miRNAs in individual samples. Finally, based on the known functions of the protein encoded by the gene bearing the miRSNP, appropriate tests should be performed to unravel functional consequences of the miRSNP, which could explain their impact on the disease risk or prognosis. In case no significant effects are observed, an alternative possibility worth considering is an indirect impact of a miRSNP on expression of other genes targeted by the same miRNA through changes in the pool of miRNA available for binding in the cell. It has been proposed that different classes of RNA transcripts – miRNAs, pseudogenes and long non-coding RNAs – compete for miRNA binding, intertwined in a large regulatory network. The “competing endogenous RNA” (ceRNA) hypothesis assumes that RNAs communicate with each other through miRNAs and miRNA recognition sequences [23]. Thus, the effect of a miRSNP may extend beyond expression of the gene bearing the polymorphism, and influence other RNAs regulated by the same miRNA.

In conclusion, polymorphisms in miRNA-binding sites not only offer a possibility of novel diagnostic and prognostic markers in hematological malignancies, but can also help to understand complex regulatory networks of miRNAs in health and disease. With the development of more sophisticated bioinformatics algorithms and accumulation of data from sequencing of cancer genomes, identification of miRSNPs of clinical utility and functional relevance for hematological malignancies should be facilitated.

Abbreviations
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CDS: Coding sequence; CML: Chronic myeloid leukemia; celfRNA: Competing endogenous RNA; DFS: Disease-free survival; DLBCL: Diffuse large B-cell lymphoma; HL: Hodgkin lymphoma; miRNA: microRNA; miRSNP: miRNA-binding site polymorphism; MM: multiple myeloma; NHL: Non-Hodgkin lymphoma; OR (95% CI): Odds ratio (95% confidence interval); OS: Overall survival; PFS: Progression-free survival; RFS: Relapse-free survival; SNP: Single nucleotide polymorphism; UTR: 3’ untranslated region.

Competing interests
The author reports no conflicts of interest.
Acknowledgements
This work was supported by the Ministry of Science and Higher Education grant no N N401 570740.

Received: 18 September 2014 Accepted: 6 November 2014
Published online: 25 November 2014

References
1. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215–233.
2. Kozomara A, Griffiths-Jones S: miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014, 42:D69–73.
3. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian miRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92–105.
4. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281–297.
5. Lawrie CH: MicroRNAs in hematological malignancies. Blood Rev 2013, 27:143–154.
6. Kluiver J, Krösen BJ, Poppema S, van den Berg A: The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia 2006, 20:1931–1936.
7. Witkos TM, Kosiacka E, Krzyzosiak WJ: Practical Aspects of microRNA Target Prediction. Curr Mol Med 2011, 11:93–109.
8. Chen K, Rajewsky N: Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 2006, 38:1452–1456.
9. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, Wu M, Shen SH: Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 2007, 35:4535–4541.
10. Saunders MA, Liang H, Li WH: Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A 2007, 104:3300–3305.
11. Salzman DW, Weidhaas JB: SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 2013, 137:55–63.
12. Mishra PJ, Bertino JR: MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009, 10:399–416.
13. de Larena CF, Navarro A, Tejero R, Tovar N, Díaz T, Cibeira MT, Rosiñol L, Ferrer G, Rovira M, Rozman M, Monzo M, Blàilda L: Impact of MiRSNP on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. Clin Cancer Res 2012, 18:3697–3704.
14. Karantza V: Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011, 30:127–138.
15. Navarro A, Muñoz C, Gaya A, Díaz-Beyá M, Gel B, Tejero R, Díaz T, Martínez A, Monzo M: MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients. PLoS One 2013, 8:e64716.
16. Xie Y, Diao L, Zhang L, Liu C, Xu Z, Liu S: A miR-SNP of the KRT81 gene is associated with the prognosis of non-Hodgkin’s lymphoma. Gene 2014, 539:198–202.
17. Melo SA, Esteller M: Disruption of microRNA nuclear transport in human cancer. Semin Cancer Biol 2014, 24:7C46–51.
18. Li Y, Gordon MM, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaa K, Oratzi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piri A, Müller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH: Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013, 121:4529–4540.
19. Yang B, Liu C, Diao L, Wang C, Guo Z: A polymorphism at the microRNA binding site in the 3′ untranslated region of C14orf101 is associated with non-Hodgkin lymphoma overall survival. Cancer Genet 2014, 207:141–146.
20. Falini B, Mantelli MP, Bolli N, Sportorelli P, Liso A, Taccani E, Hallek M: Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011, 117:1109–1120.
21. Cheng CK, Kwan TK, Cheung CY, Ng K, Liu P, Cheng SH, Chan NP, Ip RK, Wong RS, Lee V, Li CK, Yip SF, Ng MH: A polymorphism in the 3′ untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia. Haematologica 2013, 98:913–917.
22. Dzikiewicz-Krawczyk A, Maciej A, Maly E, Januszkiewicz-Lewandowska D, Mosor M, Fichna M, Strauss E, Nowak J: Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding. J Hematol Oncol 2014, 7:43.
23. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP: A cell-free hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011, 146:353–358.
24. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human MicroRNA targets. PLoS Biol 2004, 2:e363.
25. Kertesz M, Ivovino N, Unnerstall U, Gaul U, Segal E: The role of site accessibility in microRNA target recognition. Nat Genet 2007, 39:1278–1284.
26. Bao L, Zhou M, Wu L, Lu, L, Goldowitz D, Williams RW, Cui Y: PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 2007, 35:O251–54.
27. Xu Z, Taylor JA: SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009, 37:W600–605.
28. Ritchie W, Flannart S, Rasko JE: mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets. Bioinformatics 2010, 26:222–227.
29. ncRNA body map [http://www.mirnabodymap.org/]

doi:10.1186/s13045-014-0083-3

Cite this article as: Dzikiewicz-Krawczyk: MicroRNA-binding site polymorphisms in hematological malignancies. Journal of Hematology & Oncology 2014, 7:83.